Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Cancer Biomarkers Market
The global cancer biomarkers market is experiencing notable expansion, with sustained growth anticipated through the forecast period.
Market size
Growth trajectory through 2035
Cancer Biomarkers Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
Development 01
- [Additional data pending]: [Additional data pending].
Emerging opportunities added
- Expansion in emerging markets Rapidly growing healthcare infrastructure and increasing cancer awareness in regions such as Asia-Pacific and Latin America present significant growth opportunities for biomarker-based diagnostics and therapies.
- Integration with digital health and AI The convergence of biomarkers with digital health platforms and artificial intelligence offers opportunities to enhance predictive analytics, personalized medicine, and real-time patient monitoring.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $10.00 Bn
- CAGR
- 6.50%
- Expansion
- 1.9×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High development costs
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
[Additional data pending]: [Additional data pending]
Report scope
What this report answers
The specific decisions and questions covered in the 100-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Cancer Biomarkers Market today ($10.00 Bn base), and how fast will it grow at 6.5% CAGR through 2035?
- Which of Diagnostics, Therapeutics, Research Tools and other tracked segments holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Early Cancer Detection, Cancer Diagnosis, Drug Development applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do GSK plc, Pfizer Inc, Johnson & Johnson and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising cancer incidence) and top restraints (led by High development costs), with quantified CAGR impact?
- What regulatory shifts and 1 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising cancer incidence The increasing global burden of cancer, particularly breast, lung, colorectal, and prostate cancers, is driving demand for early detection and monitoring biomarkers. This trend is supported by demographic shifts and lifestyle factors contributing to higher cancer prevalence.
- Advancements in biomarker technologies Innovations in molecular diagnostics, liquid biopsy techniques, and genomic profiling are expanding the utility of biomarkers in clinical decision-making. These technologies enable minimally invasive, accurate, and scalable cancer detection and monitoring.
- Growth in pharmaceutical R&D The integration of biomarkers in drug discovery and development is accelerating, as they provide critical insights into drug efficacy, safety, and patient stratification. Regulatory agencies increasingly mandate biomarker evaluation in clinical trials.
Restraints
Holding it back
- High development costs The research, validation, and regulatory approval processes for new biomarkers are resource-intensive, limiting market entry for smaller firms and increasing overall costs for healthcare systems.
- Regulatory and reimbursement challenges Stringent regulatory pathways for biomarker approval and variability in reimbursement policies across regions can delay market adoption and constrain revenue growth.
- Data standardization and integration issues The lack of standardized protocols for biomarker validation and integration into clinical workflows poses challenges for widespread adoption and interoperability across healthcare systems.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising cancer incidence | +2.9% | Global | 2025–2035 |
| Advancements in biomarker technologies | +1.8% | Global | 2025–2035 |
| Growth in pharmaceutical R&D | +1.4% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High development costs | −1.2% | Global | 2025–2029 |
| Regulatory and reimbursement challenges | −0.8% | Global | 2025–2029 |
| Data standardization and integration issues | −0.6% | Global | 2025–2029 |
The cancer biomarkers market is segmented by cancer type, biomarker type, end user, and region. Primary segmentation dimensions include breast cancer, lung cancer, colorectal cancer, prostate cancer, and other cancer types, alongside biomarker categories such as PSA, HER-2, EGFR, KRAS, and others.
Revenue share by type · 2025 base year
% OF $10.00 BN CANCER BIOMARKERS MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $10.00 Bn Cancer Biomarkers Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Diagnostics
-
Therapeutics
-
Research Tools
-
Companion Diagnostics
By application
-
Early Cancer Detection
-
Cancer Diagnosis
-
Drug Development
-
Patient Stratification
-
Treatment Monitoring
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $10.00 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~47.5% in 2025. The region is expected to maintain a leading position in the cancer biomarkers market, driven by high cancer prevalence, strong R&D investments, and favorable regulatory frameworks supporting biomark…
Per-region detail
-
North America
The region is expected to maintain a leading position in the cancer biomarkers market, driven by high cancer prevalence, strong R&D investments, and favorable regulatory frameworks supporting biomarker innovation
-
Europe
Europe is a significant market for cancer biomarkers, characterized by robust healthcare systems, increasing adoption of advanced diagnostics, and collaborative research initiatives across member states
-
Asia-Pacific
The Asia-Pacific region is projected to experience rapid growth, fueled by rising cancer incidence, expanding healthcare infrastructure, and growing investments in biomarker research and development
-
Latin America
Growth in this region is supported by improving healthcare access, increasing awareness of cancer biomarkers, and partnerships with global diagnostic companies to enhance local capabilities
-
Middle East & Africa
The market in this region is emerging, with growth driven by rising cancer rates, government initiatives to improve healthcare, and increasing collaborations with international diagnostic firms
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The cancer biomarkers market is moderately concentrated, with a mix of multinational pharmaceutical companies, diagnostic firms, and specialized biotechnology enterprises competing for market share.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
GSK plc
Rank 01Share est. ~16%Revenue $38B FYHQ UK · London -
Pfizer Inc
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Johnson & Johnson
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Roche Holding AG
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Novartis AG
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Merck & Co., Inc
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
AbbVie Inc
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Eli Lilly and Company
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the worth of global cancer biomarkers market?
Cancer biomarkers market size was valued at USD 11.38 billion in 2020 and is projected to reach USD 45.58 billion by 2029, growing at a CAGR of 17.5% from 2022 to 2029 driven by the demand for cancer biomarkers is a paradigm shift toward personalised medicine for cancer therapy due to a lack of conventional diagnosis and treatment. -
• What is the size of the North America cancer biomarkers industry?
North America held more than 36% of the cancer biomarkers market revenue share in 2021 and will witness growth with the increase in the number of research studies proving the efficacy of biomarkers in drug discovery and development. -
• What are the upcoming trends of cancer biomarkers market, globally?
Increased government and public-private sector investments in cancer diagnostics R&D have a favorable impact on the industry. -
• What is the CAGR of cancer biomarkers market?
Cancer biomarkers market size was valued at USD 11.38 billion in 2020 and is projected to reach USD 45.58 billion by 2029, growing at a CAGR of 17.5%. -
• Which are the top companies to hold the market share in cancer biomarkers market?
Key players profiled in the report include Abbott, DiagnoCure Inc., Thermo Fisher Scientific Inc, Illumina, Inc, QIAGEN, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc, Quest Diagnostics Incorporated, Merck KGaA, Hologic, Inc. -
• Which is the largest regional market for cancer biomarkers market?
North America is the largest market for cancer biomarkers market.
The Cancer Biomarkers Market is projected to reach $18.77 Bn by 2035, up from $10.00 Bn in 2025 — a 6.50% CAGR equating to roughly 1.9× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.